GTx, Inc.;University of Tennessee Research Foundation
发明人:
Ramesh NARAYANAN,Duane D. MILLER,Thamarai PONNUSAMY,Dong-Jin HWANG,Charles B. DUKE,Christopher C. COSS,Amanda JONES,James T. DALTON
申请号：
US15830688
公开号：
US20180118663A1
申请日:
2017.12.04
申请国别(地区):
US
年份:
2018
代理人:
摘要：
This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
